AKT1 and acute myeloid leukemia: The research showed APG-2575’s antileukemic efficacy was improved by the addition of HHT in primary and AML cell lines both in vitro and in vivo.[87] Mechanistically, the resistance of APG-2575 caused by overexpressed MCL-1 was overcome by HHT by inhibiting the PI3K/AKT/GSK3 signaling pathway, which is how HHT suppressed it.